Document:

ex104.htm

    Exhibit
10.4

    
 

    PATENT,
TRADEMARK

    AND COPYRIGHT SECURITY
AGREEMENT

    

    THIS PATENT, TRADEMARK AND COPYRIGHT
SECURITY AGREEMENT (this “Agreement”) is entered into as of this 9th day of
January 2009, by and among URIGEN PHARMACEUTICALS, INC., a Delaware corporation,
and URIGEN N.A., INC., a Delaware corporation, each with its principal place of
business at 27 Maiden Lane, Suite 595, San Francisco, California, 94108 (jointly
and severally, the “Borrower”), and PLATINUM-MONTAUR LIFE SCIENCES, LLC, as
collateral agent (the “Agent”) for the investors identified in the below
referenced Purchase Agreement (collectively, together with their successors and
assigns, the “Lenders”).

    

    WHEREAS, Borrower and the
Lenders are parties to a certain Note Purchase Agreement, dated as of January 9,
2009 (as amended, restated, supplemented or extended from time to time, the
“Purchase Agreement”), and a Security Agreement, dated as of January 9, 2009
(the “Security Agreement”), which provide for, among other things: (i) the
Lenders to extend certain loans to or for the account of the Borrower; (ii) the
grant by the Borrower to the Lenders of a security interest in all of the
Borrower’s assets, including, without limitation, its patents, patent
applications, trademarks, trademark applications, goodwill, service marks, trade
names, trade styles, copyrights, copyright applications, mask works,
trade-secrets information, and other proprietary rights, together with all
additions, accessions, accessories, amendments, attachments, modifications,
substitutions, and replacements, proceeds and products of any of the foregoing,
as set forth in the Purchase Agreement and the other Transaction Documents
(capitalized terms used herein and not otherwise defined have the respective
meanings given in the Purchase Agreement); and (iii) the appointment of the
Agent as collateral agent, for the benefit of the Lenders, for purpose of this
Agreement and the Security Agreement.

    

    NOW, THEREFORE, in
consideration of the foregoing premises and the mutual covenants and agreements
contained, and for other good and valuable consideration (the receipt and
sufficiency of which are hereby acknowledged), the Borrower and the Agent, for
the benefit of the Lenders, agree as follows:

    

    1.           Security Interest in
Patents, Trademarks and Copyrights. To secure the complete and timely
satisfaction of all of Borrower’s “Obligations” (as that term is defined in the
Security Agreement) to the Lenders, the Borrower hereby grants and conveys to
the Agent, for the benefit of the Lenders, a security interest (having priority
over all other security interests) with power of sale, to the extent permitted
by law, in all of its now owned or existing, and hereafter acquired or
arising:

    

    
      	
               
      

            	
              (a)

            	
              patents,
      patent applications, including, without limitation, any invention and
      improvement to a patent or patent application, including without
      limitation those patents and patent applications listed on Schedule A
      (being sometimes referred to individually and/or collectively, the
      “Patents”);

            

    

     

    
      
         

      

      
        1

        
          

        

      

      
         

      

    

    
 

    
      	
               
      

            	
              (b)

            	
              trademarks,
      registered trademarks and trademark applications, trade names, trade
      styles, service marks, registered service marks and service mark
      applications including, without limitation, the registered trademarks,
      trademark applications, registered service marks and service mark
      applications listed on Schedule B and
      (i) all renewals thereof, (ii) all accounts receivable, income, royalties,
      damages and payments now and hereafter due and/or payable with respect
      thereto, including, without limitation, payments under all licenses
      entered into in connection therewith and damages and payments for past,
      present or future infringements and dilutions thereof, and (iii) the right
      to sue for past, present and future infringements and dilutions thereof,
      and (iv) all of the Borrower’s rights corresponding thereto throughout the
      world (all of the foregoing registered trademarks, trademark applications,
      trade names, trade styles, registered service marks and service mark
      applications, together with the items described in clauses (i)-(iv) in
      this Section 1(b), being sometimes hereinafter individually and/or
      collectively referred to as the
“Trademarks”);

            

    

    

    
      	
               
      

            	
              (c)

            	
              the
      goodwill of Borrower’s business connected with and symbolized by the
      Trademarks; and

            

    

    

    
      	
               
      

            	
              (d)

            	
              copyrights,
      and copyright applications, including without limitation, those copyrights
      listed in Schedule C
      (being sometimes referred to individually and/or collectively as the
      “Copyrights”);

            

    

    

    together
with all additions, accessions, accessories, amendments, attachments,
modifications, substitutions, and replacements, proceeds and products of the
foregoing.

    

    2.           Recording of Patents and
Trademarks. Borrower represents and warrants that (1) the patents and
patent applications listed in Schedule A, and (2) the trademark and trademark
applications described in Schedule B, have each been duly recorded in the U.S.
Patent and Trademark Office (the “PTO”); and that no other patents, patent
applications, trademarks, or trademark applications have been filed or recorded
with the PTO in which the Borrower has an interest.

    

    3.           Recording of
Copyrights.  Borrower represents and warrants that the
copyright and copyright applications described in Schedule C have been duly
recorded in the U.S. Copyright Office, and that no other copyright, and
copyright applications have been recorded in the U.S. Copyright Office, in which
the Borrower has an interest.

    

    4.           Restrictions on Future
Agreements.  Borrower will not, without the Agent’s prior
written consent, enter into any agreement, including, without limitation, any
license agreement, that is inconsistent with this Agreement, and Borrower
further agrees that it will not take any action, and will use reasonable efforts
not to knowingly permit any action to be taken by others subject to its control,
including licensees, or knowingly fail to take any action, which would affect
the validity or enforcement of the rights transferred to the Agent, for the
benefit of the Lenders, under this Agreement or the rights associated with those
Patents, Trademarks and/or Copyrights which are in Borrower’s reasonable
business judgment, necessary or desirable in the operation of Borrower’s
business.

     

    
      
         

      

      
        2

        
          

        

      

      
         

      

    

    

    5.           New Patents, Trademarks and
Copyrights.  Borrower represents and warrants that the Patents,
Trademarks, and Copyrights listed on Schedules A, B, and C, include all of the
patents, patent applications, trademark registrations, trademark applications,
service marks registrations, service mark applications, registered copyrights
and copyright applications, now owned or held by Borrower.  If, prior
to the termination of this Agreement, Borrower shall (i) create or obtain rights
to any new patents, trademarks, trademark registrations, trademark applications,
trade names, trade styles, service marks, service marks registrations, or
service mark applications, or (ii) become entitled to the benefit of any patent,
trademark, trademark registration, trademark application, trade name, trade
style, service mark, service mark registration, service mark application, the
provisions of Section 1 above shall automatically apply thereto and Borrower
shall give the Agent prompt written notice thereof.  Borrower hereby
authorizes the Agent to modify this Agreement by (a) amending Schedules A, B,
and/or C, as the case may be, to include any future patents, trademark
registrations, trademark applications, service mark registrations, service mark
applications, registered copyrights and copyright applications that are Patents,
Trademarks or Copyrights under Section 1 above, or under this Section 5 (whether
or not any such notice from Borrower has been sent or received), and (b) filing,
in addition to and not in substitution for this Agreement, a supplement or
addendum to this Agreement containing on Schedule B therein, as the case may be,
such registered trademarks, trademark applications, service marks, registered
service marks and  service mark applications that are Trademarks under
Section 1 above or this Section 5 and to take any action the Agent otherwise
deems appropriate to perfect or maintain the rights and interest of the Agent,
for the benefit of the Lender, under this Agreement with respect to such
Patents, Trademarks and Copyrights.

    

    6.           Nature and Continuation of
Security Interest; Notice to Third Parties. This Agreement has the effect
of giving third parties notice of the Agent’s Security Interest in Borrower’s
Patents, Trademarks and Copyrights.  This Agreement is made for
collateral security purposes only.  This Agreement shall create a
continuing security interest in the Patents, Trademarks and Copyrights and shall
remain in full force and effect until the liabilities and Obligations of the
Borrower to the Lenders have been paid in full, including all obligations under
the Purchase Agreement and the Transaction Documents (as defined in the Purchase
Agreement).

    

    7.           Right to Inspect;
Assignments and Security Interests.  The Agent shall have the
right, at any reasonable time upon prior written request and from time to time,
to inspect Borrower’s premises and to examine Borrower’s books, records and
operations relating to the Patents and the Trademarks, including, without
limitation, Borrower’s quality control processes; provided, that in conducting
such inspections and examinations, the Agent shall use reasonable efforts not to
disturb unnecessarily the conduct of Borrower’s ordinary business
operations.  From and after the occurrence of an event of default,
under the Purchase Agreement, or any other Transaction Documents (“Event of
Default”), Borrower agrees that the Agent, or a conservator appointed by the
Agent, shall have the right to take any action to renew or to apply for
registration of any Trademarks as the Agent or said conservator, on its sole
judgment, may deem necessary or desirable in connection with the enforcement of
the Agent’s rights hereunder.  Borrower agrees (i) except in
accordance with Borrower’s reasonable business judgment, not to sell or assign
its respective interests in the Patents, Trademarks and/or Copyrights without
the prior written consent of the Agent and the holders of a majority in
principal the amount of the Notes (as defined in the Purchase Agreement) and
(ii) to maintain the quality of any and all products in connection with which
the Trademarks are used, consistent with the quality of said products as of the
date hereof.

     

    
      
         

      

      
        3

        
          

        

      

      
         

      

    

    

    8.           Duties of
Borrower.  Borrower shall have the duty to (i) prosecute
diligently any patent application, or trademark application or service mark
application that is part of the Trademarks pending as of the date hereof or
thereafter until the termination of this Agreement, and (ii) preserve and
maintain all of Borrower’s rights in the patents, patent applications, trademark
applications, service mark applications and trademark and service mark
registrations that are part of the Patents and Trademarks.  Any
expenses incurred in connection with the foregoing shall be borne by
Borrower.  Borrower shall not, without thirty (30) days prior written
notice to the Agent, abandon any trademark or service mark that is the subject
of a registered trademark, service mark or application therefor and which, is or
shall be necessary or economically desirable in the operation of the Borrower’s
business.  The Agent shall not have any duty with respect to the
Patents, Trademarks and/or Copyrights.  Without limiting the
generality of the foregoing, the Agent shall not be under any obligation to take
any steps necessary to preserve rights in the Patents, Trademarks and/or
Copyrights against any other parties, but may do so at its option during the
continuance of an Event of Default, and all expenses incurred in connection
therewith shall be for the sole account of Borrower and added to the Obligations
and liabilities secured hereby, and by the Transaction Documents.

    

    9.           Agent’s Right to
Sue.  Upon the occurrence and during the continuance of any
Event of Default, the Agent shall have the right, for the benefit of the
Lenders, to exercise all rights and remedies available at law or in
equity.  From and after the occurrence and during the continuance of
an Event of Default, the Agent shall have the right, but shall not be obligated,
to bring suit or take any other action to enforce the Patents, Trademarks and
Copyrights and, if the Agent shall commence any such suit or take any such
action, Borrower shall, at the request of the Agent, do any and all reasonable
lawful acts and execute any and all proper documents reasonably required by the
Agent in aid of such enforcement.  Borrower shall, upon demand,
promptly reimburse and indemnify the Agent for all reasonable out-of-pocket
costs and expenses incurred by the Agent in the exercise of its rights under
this Section 9 (including, without limitation, all attorneys’
fees).  If, for any reason whatsoever, the Agent is not reimbursed
with respect to the costs and expenses referred to in the preceding sentence,
such costs and expenses shall be added to the Obligations secured
hereby.

    

    10.           Waivers.  The
Borrower waives to the extent permitted by applicable law presentment, demand,
notice, protest, notice of acceptance of this Agreement, notice of any loans
made, credit or other extensions granted, collateral received or delivered or
any other action taken in reliance hereon and all other demands and notices of
any description, except for such demands and notices as are expressly required
to be provided to the Borrower under this Agreement or any other document
evidencing the Obligations or the liabilities under the Transaction
Documents.  With respect to both the Obligations and the Collateral,
the Borrower assents to any extension or postponement of the time of payment or
any other forgiveness or indulgence, to any substitution, exchange or release of
Collateral, to the addition or release of any party or person primarily or
secondarily liable, to the acceptance of partial payment thereon and the
settlement, compromise or adjustment of any thereof, all in such manner and at
such time or times as the Agent may deem advisable.  The Agent may
exercise its rights with respect to the Collateral without resorting, or regard,
to other collateral or sources of reimbursement for Obligations.  The
Agent shall not be deemed to have waived any of its rights with respect to the
Obligations or the Collateral unless such waiver is in writing and signed by the
Agent.  No delay or omission on the part of the Agent in exercising
any right shall operate as a waiver of such right or any other
right.  A waiver on any one occasion shall not bar or waive the
exercise of any right on any future occasion.  All rights and remedies
of the Agent in the Obligations or the Collateral, whether evidenced hereby or
by any other instrument or papers, are cumulative and not exclusive of any
remedies provided by law or any other agreement, and may be exercised separately
or concurrently.

     

    
      
         

      

      
        4

        
          

        

      

      
         

      

    

    

    11.           Successors and
Assigns. This Agreement shall be binding upon the Borrower, its
respective successors and permitted assigns, and shall inure to the benefit of
and be enforceable by the Agent and its successors and
assigns.  Without limiting the generality of the foregoing sentence,
the Agent may assign or otherwise transfer any agreement or any note held by it
evidencing, securing or otherwise executed in connection with the Obligations,
or sell participations in any interest therein, to any other person or
entity.

    

    12.           General;
Term.

    

    (a)           This
Agreement may not be amended or modified except by a writing signed by the
Borrower and the Agent, nor may the Borrower assign any of its rights
hereunder.  This Agreement and the terms, covenants and conditions
hereof shall be construed in accordance with, and governed by, the laws of the
State of New York (without giving effect to any conflicts of law provisions
contained therein).  In the event that any Collateral stands in the
name of the Borrower and another or others jointly, as between the Agent and the
Borrower, the Agent may deal with the same for all purposes as if it belonged to
or stood in the name of the Borrower alone.

    

    (b)           This
Agreement and the security interests granted herein shall terminate on the date
on which all payments under the Notes (as defined in the Purchase Agreement)
have been indefeasibly paid or satisfied in full (including as a result of the
conversion in full of the Notes) and all other obligations have been paid or
discharged (other than contingent indemnification obligations).

     

    
      
         

      

      
        5

        
          

        

      

      
         

      

    

    

    13.           WAIVER OF JURY TRIAL;
VENUE.

    

    THE
BORROWER HEREBY WAIVES TRIAL BY JURY IN ANY LITIGATION IN ANY COURT WITH RESPECT
TO, IN CONNECTION WITH OR, ARISING OUT OF:  (A) THIS AGREEMENT OR ANY
OTHER INSTRUMENT OR DOCUMENT DELIVERED IN CONNECTION HEREWITH; (B) THE VALIDITY,
INTERPRETATION, COLLECTION OR ENFORCEMENT THEREOF; OR (C) ANY OTHER CLAIM OR
DISPUTE HOWEVER ARISING BETWEEN THE BORROWER AND THE LENDERS OR THE AGENT IN
RESPECT OF THIS AGREEMENT.

    

    THE
BORROWER AGREES THAT ANY SUIT FOR THE ENFORCEMENT OF THE OBLIGATIONS, ARISING
OUT OF OR IN ANY MANNER RELATING TO THIS AGREEMENT OR ANY TRANSACTION RELATING
TO ANY TRANSACTION DOCUMENT MAY BE BROUGHT IN THE COURTS OF THE STATE OF NEW
YORK IN THE CITY OF NEW YORK OR ANY FEDERAL COURT SITTING THEREIN AND CONSENTS
TO THE NON-EXCLUSIVE JURISDICTION OF SUCH COURT AND TO SERVICE OF PROCESS IN ANY
SUCH SUIT BEING MADE UPON THE BORROWER BY MAIL AT THE ADDRESS SPECIFIED IN THE
PURCHASE AGREEMENT. THE BORROWER HEREBY WAIVES ANY OBJECTION THAT IT MAY NOW OR
HEREAFTER HAVE TO THE VENUE OF ANY SUCH SUIT OR ANY SUCH COURT OR THAT SUCH SUIT
WAS BROUGHT IN AN INCONVENIENT COURT.  THE BORROWER SHALL NOT BE
ENTITLED IN ANY SUCH ACTION OR PROCEEDING TO ASSERT ANY DEFENSE GIVEN OR ALLOWED
UNDER THE LAWS OF ANY STATE OTHER THAN THE STATE OF NEW YORK UNLESS SUCH DEFENSE
IS ALSO GIVEN OR ALLOWED BY THE LAWS OF THE STATE OF NEW
YORK.  NOTHING IN THIS SECTION SHALL AFFECT OR IMPAIR IN ANY MANNER OR
TO ANY EXTENT THE RIGHT OF THE AGENT TO COMMENCE LEGAL PROCEEDINGS OR OTHERWISE
PROCEED AGAINST THE BORROWER IN ANY JURISDICTION IN WHICH ANY COLLATERAL IS
LOCATED, THE BORROWER CONDUCTS ACTIVITIES OR WHERE LEGAL PROCEEDINGS MAY BE
NECESSARY IN ORDER TO COLLECT OR ENFORCE THE OBLIGATIONS OR TO SERVE PROCESS IN
ANY MANNER PERMITTED BY LAW.

    

    

    [Signature
Page Follows]

     

     

     

     

     

    
      
         

      

      
        6

        
          

        

      

      
         

      

    

    

    

    IN WITNESS WHEREOF, the
parties have executed this Agreement as of the date first written
above.

     

     

    
      
        
          
            
              	 	 	BORROWER:	 
	 	 	 	 
	In
      the Presence of:  	 	URIGEN PHARMACEUTICALS,
      INC.	 
	 	 	 	 	 
	
                       

                    	 	
                      By:
      

                    	/s/ William
      J. Garner, M.D.	 
	Witness   	 	 	Name:
      William J. Garner, M.D.	 
	 	 	 	Title:
      Chief Executive Office	 
	 	 	 	 	 

            

          

        

      

    

     

    
      
        
          
            	In
      the Presence of:  	 	URIGEN N.A.,
    INC.	 
	 	 	 	 	 
	
                  	 	
                    By:
      

                  	/s/ Martin
      E. Shmagin  	 
	Witness   	 	 	Name:
      Martin E. Shmagin	 
	 	 	 	Title:
      Chief Financial Officer	 
	 	 	 	 	 

          

        

      

    

    
       

      
        
          
            
              
                	 	 	AGENT:	 
	 	 	 	 
	In
      the Presence of:	 	
                        PLATINUM-MONTAUR
      LIFE SCIENCES, LLC

                      	 
	 	 	 	 	 
	
                      	 	
                        By:
      

                      	/s/ Michael
      M. Goldberg	 
	Witness    	 	 	Name:
      Michael M. Goldberg	 
	 	 	 	Title:
      Portfolio Manager	 
	 	 	 	 	 

              

            

          

        

      

    

    

     

     

    
      
         

      

      
        7

        
          

        

      

      
         

      

    

     

    

    STATE OF
CALIFORNIA                )

    ) SS.:

    COUNTY OF
SAN FRANCISCO        )

    

    On the
29th day of December, in the year 2009, before me, the undersigned, a notary
public in and for said state, personally appeared William J. Garner, personally
known to me or proved to me on the basis of satisfactory evidence to be the
individual(s) whose name(s) is (are) subscribed to the within instrument and
acknowledged to me that he/she/they executed the same in his/her/their
capacity(ies), and that by his/her/their signature(s) on the instrument, the
individual(s), or the person upon behalf of which the individual(s) acted,
executed the instrument.

     

    
      
        
          
            	 	 	 	 
	
                     

                  	
                     

                  	/s/
      Ira Komar	 
	 	 	Notary
      Public	 
	 	 	 	 

          

        

      

    

    

    STATE OF
CALIFORNIA                  )

    ) SS.:

    COUNTY OF
SAN FRANCISCO        )

    

    On the
29th day of December, in the year 2009, before me, the undersigned, a notary
public in and for said state, personally appeared Martin E. Shmagin, personally
known to me or proved to me on the basis of satisfactory evidence to be the
individual(s) whose name(s) is (are) subscribed to the within instrument and
acknowledged to me that he/she/they executed the same in his/her/their
capacity(ies), and that by his/her/their signature(s) on the instrument, the
individual(s), or the person upon behalf of which the individual(s) acted,
executed the instrument.

     

    
      
        
          
            
              	 	 	 	 
	
                       

                    	
                       

                    	/s/
      Ira Komar	 
	 	 	Notary
      Public	 
	 	 	 	 

            

          

        

    

    STATE OF
_______________                  )

    ) SS.:

    COUNTY OF
__________________        )

    

    On the
_____ day of January, in the year 2009, before me, the undersigned, a notary
public in and for said state, personally appeared ________________, personally
known to me or proved to me on the basis of satisfactory evidence to be the
individual(s) whose name(s) is (are) subscribed to the within instrument and
acknowledged to me that he/she/they executed the same in his/her/their
capacity(ies), and that by his/her/their signature(s) on the instrument, the
individual(s), or the person upon behalf of which the individual(s) acted,
executed the instrument.

     

    
       

      
        
          
            
              	 	 	 	 
	
                       

                    	
                       

                    	 	 
	 	 	Notary
      Public	 
	 	 	 	 

            

          

        

      

    

    
 

    
      
         

      

      
        8

        
          

        

      

      
         

      

    

    

    

    Schedule
A

    Patents
and Patent Applications

    

    Patent Filings for
URG101

     

    

     

    
      	
              1.  

            	
              Urigen
      Patent Application

            

    

     

    
      	
              Title:

            	
              “KITS
      AND IMPROVED COMPOSITIONS FOR TREATING LOWER URINARY TRACT
      DISORDERS”

            

    

     

    
      	
              Abstract:

            	
              Superior
      buffered formulations and their kits for treating lower urinary tract
      symptoms and disorders are provided in the invention. In particular
      superior buffered formulations have demonstrated improvement for treating
      lower urinary tract symptoms of patients experiencing severe pain and/or
      urgency of the bladder and associated areas of the lower urinary
      tract.

            

    

     

    
      	
              Inventor:

            	
              FLASHNER
      MICHAEL; FRANKLIN AMIE E; GARNER WILLIAM J; PARSONS C
    LOWELL

            

    

     

    
      	
              Assignee:

            	
              Urigen
      Pharmaceuticals, Inc.

            

    

     

    
      	
              Attorney:

            	
              Benjamin
      Borson, PhD, JD, Borson Law

            

    

     

    
      	
              Priority
      date:

            	
              U.S.
      Provisional Application Ser. No. 60/752,287 filed on Dec. 19, 2005 and PCT
      filing US 2006/001388 Jan. 13, 2006

            

    

     

    Jurisdictions:

     

    
      	
              1.  

            	
              United
      States - pending

            

    

     

    
      	
              2.  

            	
              Australia:
      2006204769 - pending

            

    

     

    
      	
              3.  

            	
              Europe:
      06718460.6 - pending

            

    

     

    
      	
              4.  

            	
              Japan:  -
      pending

            

    

     

    
      	
              5.  

            	
              Korea:
      10-2007-7018672 - pending

            

    

     

    
      	
              6.  

            	
              Canada
      – pending

            

    

     

    
      	
              2.  

            	
              UCSD
      Patent

            

    

     

    
      	
              Title:

            	
              “NOVEL
      INTERSTITIAL THERAPY FOR IMMEDIATE SYMPTOM RELIEF AND CHRONIC THERAPY IN
      INTERSTITIAL CYSTITIS”

            

    

     

    
      	
              Abstract:

            	
              The
      present invention relates to a disorder of the lower urinary tract, and in
      particular, reducing the symptoms (including treatment) of interstitial
      cystitis in vivo. In a preferred embodiment, the present invention relates
      to treatment formulations and methods for reducing interstitial cystitis
      in patients. In one embodiment, the present invention contemplates a
      composition comprising: a) a heparinoid, b) a local anesthetic, and c) a
      buffering compound.

            

    

     

    
      
         

      

      
        9

        
          

        

      

      
         

      

    

     

    
      	
              Inventor:

            	
              C.
      Lowell Parsons

            

    

     

    
      	
              Assignee:

            	
              The
      Regents of the University of
California

            

    

     

    
      	
              Licensee:

            	
              Urigen
      Pharmaceuticals

            

    

     

    
      	
              Attorney:

            	
              Steve
      Reiter, PhD, JD, Foley Lardner LLP

            

    

     

    
      	
              Priority
      date:

            	
              U.S.
      Provisional Application Ser. No. 60/540,186 filed on Jan. 28,
      2004

            

    

     

    Jurisdictions:

     

    
      	
              1.  

            	
              United
      States: US 7,414,039; additional composition of matter claims
      pending

            

    

     

    
      	
              2.  

            	
              Australia:
      AU2005209322 - pending

            

    

     

    
      	
              3.  

            	
              Canada:
      CA2554489 – pending

            

    

     

    
      	
              4.  

            	
              Europe:
      05712839.9 - pending

            

    

     

    Patent Filings for
URG300

    

    
      	
              1.  

            	
              Urigen
      Patent Application

            

    

     

    
      	
              Title:

            	
              Urethral
      Suppositories for Overactive
Bladder

            

    

     

    
      	
              Abstract:

            	
              This
      invention is directed to buffered urethral suppositories for treatment of
      overactive bladder (OAB), and methods for their use.  In
      particular, this invention relates to suppositories incorporating mixed
      anti-cholinergic agents and uses thereof to treat symptoms of overactive
      bladder.

            

    

     

    
      	
              Inventors:

            	
              Amie
      E Franklin, Dennis Giesing

            

    

     

    
      	
              Assignee:

            	
              Urigen
      Pharmaceuticals, Inc.

            

    

     

    
      	
              Attorney:

            	
              Benjamin
      Borson, PhD, JD, Borson Law

            

    

     

    
      	
              Priority
      date:

            	
              United
      States Provisional Patent Application No: 60/891,454, filed February 23,
      2007

            

    

     

    
      	
              Jurisdictions:

            	
              PCT,
      national stage filings not initiated
yet

            

    

     

    
      	
              2.  

            	
              Kalium
      U. S. Patent licensed by Urigen

            

    

     

    
      	
              Title:

            	
              Method
      of delivering therapeutic agents to the urethra and an urethral
      suppository

            

    

     

    
      	
              Abstract:

            	
              A
      urethral suppository having a shaft shaped for cooperating with the action
      of the periurethral musculature to retain the suppository within the
      urethra, and having a knob extending from an end of the shaft sized to
      prevent over insertion of the suppository. A method of delivering one or
      more therapeutic agents to the urethra and associated structures, the
      method involving insertion of the urethral suppository into the
      urethra.

            

    

     

    
      
         

      

      
        10

        
          

        

      

      
         

      

    

     

    
      	
              Inventor:

            	
              Mulholland;
      S. Grant

            

    

     

    
      	
              Assignee:

            	
              Kalium,
      Inc.

            

    

     

    
      	
              Licensee:

            	
              Urigen
      Pharmaceuticals

            

    

     

    
      	
              Attorney:

            	
              Benjamin
      Borson, PhD, JD, Borson Law

            

    

     

    
      	
              Priority
      date:

            	
              November
      10, 1999

            

    

     

    
      	
              Jurisdiction:

            	
              United
      States issued Patent 6,464,670

            

    

     

    
      	
              3.  

            	
              Kalium
      U.S. Patent licensed by Urigen

            

    

     

    
      	
              Title:

            	
              Reinforced
      urethral suppository

            

    

     

    
      	
              Abstract:

            	
              A
      urethral suppository comprising a non-meltable base member sized to
      prevent insertion of the base member into the urethra, a non-meltable
      reinforcement projecting from the base member, and a meltable portion
      formed around a portion of the
reinforcement.

            

    

     

    
      	
              Inventors:

            	
              Mulholland;
      S. Grant, Zupkas; Paul

            

    

     

    
      	
              Assignee:

            	
              Kalium,
      Inc.

            

    

     

    
      	
              Licensee:

            	
              Urigen
      Pharmaceuticals

            

    

     

    
      	
              Attorney:

            	
              Benjamin
      Borson, PhD, JD, Borson Law

            

    

     

    
      	
              Priority
      date:

            	
              August
      30, 2001

            

    

     

    
      	
              Jurisdiction:

            	
              United
      States issued Patent 7,267,670

            

    

     

    
      	
              4.  

            	
              Kalium
      Patent Application licensed by
Urigen

            

    

     

    
      	
              Title:

            	
              Transluminal
      drug delivery methods and devices

            

    

     

    
      	
              Abstract:

            	
              A
      urethral suppository include a carrier base material, an anesthetic agent,
      and a buffering agent formed into a solid structure configured for
      insertion into a patient’s urethra for the treatment of interstitial
      cystitis or the prevention of pain prior to a urethral
      procedure.

            

    

     

    
      	
              Inventors:

            	
              C.
      Lowell Parsons, Paul Zupkas

            

    

     

    
      	
              Assignee:

            	
              Kalium,
      Inc.

            

    

     

    
      	
              Licensee:

            	
              Urigen
      Pharmaceuticals, Inc.

            

    

     

    
      	
              Attorney:

            	
              Benjamin
      Borson, PhD, JD, Borson Law

            

    

     

    
      	
              Priority
      date:

            	
              U.S.
      Application Ser. No. 340071 (20070172507) filed on January 26, 2006 and
      U.S. Divisional Application CIP  Ser. No.
      475809  (20070172508)

            

    

     

    Jurisdictions:

     

    
      	
              1.  

            	
              United
      States – pending

            

    

     

    
      	
              2.  

            	
              PCT
      –                      PCT/US2007/061106
      application number, publication No. W0 2007/087624 -
    pending

            

    

     

    
      
         

      

      
        11

        
          

        

      

      
         

      

    

    

    Schedule
B

    Trademarks
and Trademark Applications

    

    

    
      	
              1.  

            	
              There
      is one registered trademark “Urigen” is a word mark, information from
      USPTO provided below.

            

    

     

    
      
        	
                 
      

              	
                Word
      Mark

              	
                URIGEN

              
	 	 	 
	 	      
                Goods
      and Services

              	      
                IC
      005. US 006 018 044 046 051 052. G & S: Pharmaceutical and medicinal
      preparations for the treatment of urological disorders. FIRST USE:
      20060101. FIRST USE IN COMMERCE: 20060101

              
	 	 	 
	 	Standard
      Characters Claimed	 
	 	 	 
	 	Mark
      Drawing Code	      
                (4)
      STANDARD CHARACTER MARK

              
	 	 	 
	 	      
                Serial
      Number

              	      
                77014140

              
	 	 	 
	 	Filing
      Date	      
                October
      4, 2006

              
	 	 	 
	 	      
                Current
      Filing Basis

              	      
                1A

              
	 	 	 
	 	      
                Original
      Filing Basis

              	1A
	 	 	 
	 	      
                Published
      for Opposition

              	      
                November
      6, 2007

              
	 	 	 
	 	      
                Registration
      Number

              	      
                3371356

              
	 	 	 
	 	      
                International
      Registration Number

              	      
                0921047

              
	 	 	 
	 	      
                Registration
      Date

              	      
                January
      22, 2008

              
	 	 	 
	 	      
                Owner

              	      
                (REGISTRANT)
      Urigen N.A., Inc. CORPORATION DELAWARE Suite 235 875 Mahler Road
      Burlingame CALIFORNIA 94010

              
	 	 	 
	 	      
                Attorney
      of Record

              	      
                David
      M. Kohn

              
	 	 	 
	 	      
                Type
      of Mark

              	      
                TRADEMARK

              
	 	 	 
	 	      
                Register

              	      
                PRINCIPAL

              
	 	 	 
	 	      
                Live/Dead
      Indicator

              	      
                LIVE

              

      

    

     

     

    
      
         

      

      
        12

        
          

        

      

      
         

      

    

    

      Schedule
C

      
        Copyrights
and Copyright Applications

         

      

    

     

     

    

    There are
no copyright or copyright applications.

    

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    13ex105.htm

    Exhibit 10.5

    GUARANTY

    

    GUARANTY (the “Guaranty”),
dated as of January 9, 2009, by Urigen N.A., Inc., a Delaware corporation with
an address of 27 Maiden Lane, Suite 595, San Francisco, California, 94108 (the
“Guarantor”), in favor of the Purchasers identified in the Purchase Agreement
(as defined below)  (collectively, “Secured Parties”).

    

    WHEREAS, the Guarantor is a
subsidiary or affiliate of Urigen Pharmaceuticals, Inc. (the “Borrower”);
and

    

    WHEREAS, in accordance with
certain senior secured convertible notes, dated as of the date hereof (the
“Notes”), executed by the Borrower, and certain related agreements between the
Borrower and the Secured Parties (collectively, as amended, restated, or
extended from time to time, the “Loan Documents”), the Secured Parties have
agreed to loan to the Borrower up to Two Hundred Fifty-Seven Thousand Dollars
($257,000) (the “Loan”); and

    

    WHEREAS, the Secured Parties’
willingness to extend the loan is conditioned upon the Guarantor executing and
delivering this Guaranty; and

    

    WHEREAS, the aforesaid Loan
will be beneficial to the Guarantor inasmuch as the proceeds of the Loan to the
Borrower will indirectly benefit the Guarantor;

    

    NOW, THEREFORE, in order to
induce the Secured Parties to make the Loan to the Borrower pursuant to the Loan
Documents, and for other good and valuable consideration, the receipt and
sufficiency of which is hereby acknowledged by the Guarantor, the Guarantor
hereby agrees as follows:

    

    1.           Guaranty of Payment and
Performance.  The Guarantor hereby guarantees to the Secured
Parties the full and punctual payment when due (whether at maturity, by
acceleration or otherwise), and the performance, of all liabilities, agreements
and other obligations of the Borrower to the Secured Parties, whether direct or
indirect, absolute or contingent, due or to become due, secured or unsecured,
now existing or hereafter arising or acquired (whether by way of discount,
letter of credit, lease, loan, overdraft or otherwise), including without
limitation all obligations under the Note (collectively, the
“Obligations”).  This Guaranty is an absolute, unconditional and
continuing guaranty of the full and punctual payment and performance of the
Obligations and not of their collectibility only and is in no way conditioned
upon any requirement that the Secured Parties first attempt to collect any of
the Obligations from the Borrower or resort to any security or other means of
obtaining their payment.  Should the Borrower default in the payment
or performance of any of the Obligations, the obligations of the Guarantor
hereunder shall become immediately due and payable to the Secured Parties,
without demand or notice of any nature, all of which are expressly waived by the
Guarantor.  Payments by the Guarantor hereunder may be required by the
Secured Parties on any number of occasions.

    

    2.           Guarantor’s Agreement to
Pay.  The Guarantor further agrees, as the principal obligor
and not as a guarantor only, to pay to the Secured Parties, on demand, all
reasonable costs and expenses (including court costs and reasonable legal
expenses) incurred or expended by the Secured Parties in connection with
enforcement of this Guaranty,  together with interest on amounts
recoverable under this Guaranty from the time such amounts become due under this
Guaranty until payment, at the rate per annum equal to the default rate set
forth in the Note; provided that if such interest exceeds the maximum amount
permitted to be paid under applicable law, then such interest shall be reduced
to such maximum permitted amount.

     

    
      
         

      

      
        1

        
          

        

      

      
         

      

    

    

    3.           Unlimited
Guaranty.  The liability of the Guarantor hereunder shall be
unlimited to the extent of the Obligations and the other obligations of the
Guarantor hereunder (including, without limitation, under Section 2
above).  The Guarantor hereby covenants not to take any action that
would constitute (or otherwise cause) an Event of Default under the
Notes.

    

    4.           Waivers by Guarantor; Secured Party’s
Freedom to Act.  The Guarantor agrees that the Obligations will
be paid and performed strictly in accordance with their respective terms
regardless of any law, regulation or order now or hereafter in effect in any
jurisdiction affecting any of such terms or the rights of the Secured Parties
with respect thereto.  The Guarantor waives presentment, demand,
protest, notice of acceptance, notice of Obligations incurred and all other
notices of any kind, all defenses which may be available to Borrower by virtue
of any valuation, stay, moratorium law or other similar law now or hereafter in
effect, any right to require the marshalling of assets of the Borrower, and all
suretyship defenses generally. Without limiting the generality of the foregoing,
the Guarantor agrees to the provisions of any instrument evidencing, securing or
otherwise executed in connection with any Obligation and agrees that the
obligations of the Guarantor hereunder shall not be released or discharged, in
whole or in part, or otherwise affected by (i) the failure of any Secured
Party to assert any claim or demand or to enforce any right or remedy against
the Borrower; (ii) any extensions or renewals of any Obligation;
(iii) any rescissions, waivers, amendments or modifications of any of the
terms or provisions of any agreement evidencing, securing or otherwise executed
in connection with any Obligation (provided, that, the obligations of the
Guarantor hereunder shall be appropriately modified to reflect any amendment or
modification of the Obligations); (iv) the substitution or release of any
entity primarily or secondarily liable for any Obligation; (v) the adequacy
of any rights any Secured Party may have against any collateral or other means
of obtaining repayment of the Obligations; (vi) the impairment of any
collateral securing the Obligations, including without limitation the failure to
perfect or preserve any rights a Secured Party might have in such collateral or
the substitution, exchange, surrender, release, loss or destruction of any such
collateral; or (vii) any other act or omission which might in any manner or
to any extent vary the risk of the Guarantor or otherwise operate as a release
or discharge of any other guarantor, all of which may be done without notice to
the Guarantor.

    

    5.           Unenforceability of Obligations
Against Borrower.  If for any reason the Borrower has no legal
existence or is under no legal obligation to discharge any of the Obligations,
or if any of the Obligations have become irrecoverable from the Borrower by
operation of law or for any other reason, this Guaranty shall nevertheless be
binding on the Guarantor to the same extent as if the Guarantor at all times had
been the principal obligor on all such Obligations. In the event that
acceleration of the time for payment of the Obligations is stayed upon the
insolvency, bankruptcy or reorganization of the Borrower, or for any other
reason, all such amounts otherwise subject to acceleration under the terms of
any agreement evidencing, securing or otherwise executed in connection with any
Obligation shall be immediately due and payable by the Guarantor.

     

    
      
         

      

      
        2

        
          

        

      

      
         

      

    

    

    6.           Subrogation;
Subordination.  Until the payment and performance in full of
all Obligations, the Guarantor shall not exercise any rights against the
Borrower arising as a result of payment by any Guarantor hereunder, by way of
subrogation or otherwise, and will not prove any claim in competition with any
Secured Party or its affiliates in respect of any payment hereunder in
bankruptcy or insolvency proceedings of any nature; the Guarantor will not claim
any set-off or counterclaim against the Borrower in respect of any liability of
the Guarantor to the Borrower; and the Guarantor waives any benefit of and any
right to participate in any collateral which may be held by any Secured
Party.  The payment of any amounts due with respect to any
indebtedness of the Borrower now or hereafter held by the Guarantor is hereby
subordinated to the prior payment in full of the Obligations.  The
Guarantor agrees that after the occurrence of any default in the payment or
performance of the Obligations, after the expiration of any applicable cure
period, it will not demand, sue for or otherwise attempt to collect after such
time any such indebtedness of the Borrower to the Guarantor until the
Obligations shall have been paid in full. If, notwithstanding the foregoing
sentence, the Guarantor shall collect, enforce or receive any amounts in respect
of such indebtedness, such amounts shall be collected, enforced and received by
the Guarantor as trustee for the Secured Parties and be paid over to the Secured
Parties on account of the Obligations without affecting in any manner the
liability of the Guarantor under the other provisions of this
Guaranty.

    

    7.           Further
Assurances.  The Guarantor agrees to do all such things and
execute all such documents, as a Secured Party may consider reasonably necessary
or desirable to give full effect to this Guaranty and to perfect and preserve
the rights and powers of a Secured Party hereunder.

    

    8.           Termination;
Reinstatement.  This Guaranty shall remain in full force and
effect until the earlier of: (i) the Obligations are paid in full or otherwise
satisfied (including by the conversion in full of the Notes) (other than
contingent indemnity obligations), and not subject to any recapture or
preference in bankruptcy or similar proceedings, and the Secured Parties have no
further commitment to extent credit to the Borrower or (ii) the Secured Parties
are given written notice of the Guarantor’s intention to discontinue this
Guaranty, notwithstanding any intermediate or temporary payment or settlement of
the whole or any part of the Obligations.  No such notice under (ii)
above shall be effective against a Secured Party unless received and
acknowledged by an officer of a Secured Party.  Without limiting the
generality of the foregoing sentence, the Guarantor will be released from all
liability hereunder concurrently with either the repayment of in full of all
amounts owed under the Notes or the conversion in full of the
Notes.   No notice under (ii) above shall affect any rights of a
Secured Party or of any affiliate hereunder with respect to any Obligations
incurred prior to such notice.  This Guaranty shall continue to be
effective or be reinstated, notwithstanding any notice or termination, if at any
time any payment made or value received with respect to an Obligation is
rescinded or must otherwise be returned by a Secured Party upon the insolvency,
bankruptcy or reorganization of the Borrower, or otherwise, all as though such
payment had not been made or value received.

     

    
      
         

      

      
        3

        
          

        

      

      
         

      

    

    

    9.           Successors and
Assigns.  This Guaranty shall be jointly and severally binding
upon the Guarantor, its successors and assigns, and shall inure to the benefit
of and be enforceable by the Secured Parties and their successors, transferees
and assigns.  Without limiting the generality of the foregoing
sentence, the Secured Parties may assign or otherwise transfer any agreement or
any note held by it evidencing, securing or otherwise executed in connection
with the Obligations, or sell participations in any interest therein, to any
other person or entity, and such other person or entity shall thereupon become
vested, to the extent set forth in the agreement evidencing such assignment,
transfer or participation, with all the rights in respect thereof granted to the
Secured Parties herein.

    

    10.           Amendments and
Waivers.  No amendment or waiver of any provision of this
Guaranty nor consent to any departure by the Guarantor therefrom shall be
effective unless the same shall be in writing and signed by the Secured Parties
holding a majority of the principal amount of the Notes.  No failure
on the part of a Secured Party to exercise, and no delay in exercising, any
right hereunder shall operate as a waiver thereof; nor shall any single or
partial exercise of any right hereunder preclude any other or further exercise
thereof or the exercise of any other right.

    

    11.           Notices.  All
notices and other communications called for hereunder shall be made in writing
and, unless otherwise specifically provided herein, shall be deemed to have been
duly made or given when delivered by hand or mailed first class mail postage
prepaid or, in the case of telegraphic or telexed notice, when transmitted,
answer back received, addressed as follows: if to the Guarantor, at the address
set forth above, and if to a Secured Party, at the address set forth in the
Purchase Agreement (as defined in the Note).

    

    12.           Governing Law; Consent to
Jurisdiction.  This Guaranty shall be governed by, and
construed in accordance with, the laws of the State of New York without
reference to its conflicts of laws provisions.  The Guarantor agrees
that any suit for the enforcement of this Guaranty may be brought in the courts
of the State of New York or any federal court sitting therein and consents to
the non-exclusive jurisdiction of such court and to service of process in any
such suit being made upon the Guarantor by mail at the address specified in
Section 11 hereof.  The Guarantor hereby waives any objection that it
may now or hereafter have to the venue of any such suit or any such court or
that such suit was brought in an inconvenient court.  Any enforcement
action relating to this Guarantee may be brought by motion for summary judgment
in lieu of a complaint pursuant to Section 3213 of the New York Civil Practice
Law and Rules.  In no event shall the rate of interest payable
hereunder exceed the maximum rate (if any) permitted by applicable
law.

    

    13.           WAIVER
OF JURY TRIAL. THE GUARANTOR AND, BY THEIR ACCEPTANCE OF THIS GUARANTY, EACH
SECURED PARTY, HEREBY WAIVES TRIAL BY JURY IN ANY LITIGATION IN ANY COURT WITH
RESPECT TO, IN CONNECTION WITH, OR ARISING OUT OF: (A) THIS GUARANTY OR ANY
OTHER INSTRUMENT OR DOCUMENT DELIVERED IN CONNECTION WITH THE OBLIGATIONS;
(B) THE VALIDITY, INTERPRETATION, COLLECTION OR ENFORCEMENT THEREOF; OR
(C) ANY OTHER CLAIM OR DISPUTE HOWEVER ARISING BETWEEN THE GUARANTOR AND
ANY SECURED PARTY.

     

    
      
         

      

      
        4

        
          

        

      

      
         

      

    

    

    14.           Certain
References.  All pronouns and any variations thereof shall be
deemed to refer to the masculine, feminine, neuter, singular or plural, as the
identity of the person, persons, entity or entities may require.  The
terms “herein”, “hereof” or “hereunder” or similar terms used in this Guaranty
refer to this entire Guaranty and not only to the particular provision in which
the term is used.

    

    15.           Miscellaneous.  This
Guaranty, together with the Security Agreement, delivered by the Guarantor as of
the date hereof to the Secured Parties, constitutes the entire agreement of the
Guarantor with respect to the matters set forth herein.  The rights
and remedies herein provided are cumulative and not exclusive of any remedies
provided by law or any other agreement, and this Guaranty shall be in addition
to any other guaranty of the Obligations.  The invalidity or
unenforceability of any one or more sections of this Guaranty shall not affect
the validity or enforceability of its remaining provisions. Captions are for the
ease of reference only and shall not affect the meaning of the relevant
provisions.  The meanings of all defined terms used in this Guaranty
shall be equally applicable to the singular and plural, masculine, feminine and
generic forms of the terms defined.

    

    

     

     

     

     

     

    
 

    
      
         

      

      
        5

        
          

        

      

      
         

      

    

     

     

    IN WITNESS WHEREOF, the
Guarantor has caused this Guaranty to be executed and delivered as of the date
appearing in the introductory paragraph of this Guaranty.

    

     

    
      URIGEN
N.A., INC.

    

     

    
      By: /s/ Martin E.
Shmagin 

      
        

      

           Name:
Martin E. Shmagin

           Title:
Chief Financial Officer

     

     

     

     

     

     

     

     

     

     

     

     

    6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00152-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00152-of-00352.parquet"}]]